Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Unionand several other countries for the prevention of venous thromboembolism inadult patients undergoing elective hip or knee replacement surgery and is inadvanced clinical development for the treatment of thromboembolic disorders. The gene discussed is F10; the disease is venous thromboembolism.